|
Aug 7
|
Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem
|
|
Aug 2
|
Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Jul 31
|
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
|
|
Jul 31
|
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
|
|
Jul 31
|
Corcept: Q2 Earnings Snapshot
|
|
Jul 31
|
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
|
|
Jul 31
|
Insiders Favor These 3 High Growth Companies
|
|
Jul 30
|
What To Expect From Corcept’s (CORT) Q2 Earnings
|
|
Jul 28
|
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)
|
|
Jul 27
|
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk
|
|
Jul 25
|
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant
|
|
Jul 24
|
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
|
|
Jul 23
|
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects
|
|
Jul 21
|
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching
|
|
Jul 17
|
3 Reasons CORT is Risky and 1 Stock to Buy Instead
|
|
Jun 30
|
Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index
|
|
Jun 26
|
5 Insightful Analyst Questions From Corcept’s Q1 Earnings Call
|
|
Jun 3
|
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday
|
|
Jun 2
|
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment
|
|
Jun 2
|
Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial
|